Jackson C E, Barohn R J, Gronseth G, Pandya S, Herbelin L
University of Texas Health Science Center, San Antonio, TX, USA.
Muscle Nerve. 2008 Apr;37(4):473-6. doi: 10.1002/mus.20958.
We developed a disease-specific, 10-point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high-dose beta interferon-1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle testing, handgrip dynamometry, and the amyotrophic lateral sclerosis (ALS) functional rating scale (ALSPRS). Compared to these other outcome measures, the IBMFRS was also the most sensitive measure of change over the course of the study.
我们为包涵体肌炎患者开发了一种疾病特异性的10分功能评定量表（IBMFRS）。在一项关于高剂量β-干扰素-1a临床安全性和耐受性的多中心试点试验中，IBMFRS被用作次要结局指标。在该试验中，28例包涵体肌炎患者在基线时以及随后6个月每月完成一次IBMFRS评定。IBMFRS与最大自主等长收缩、徒手肌力测试、握力测量以及肌萎缩侧索硬化功能评定量表（ALSPRS）显示出具有统计学意义的相关性（P < 0.001）。与这些其他结局指标相比，IBMFRS也是研究过程中变化最敏感的指标。
